US ‘Blocking-Patent’ Doctrine Comes Under Attack
A US court doctrine that has invalidated patents covering major drugs such as Ampyra and Restasis is under attack from petitions to the US Supreme Court filed by Acorda and Allergan.
A US court doctrine that has invalidated patents covering major drugs such as Ampyra and Restasis is under attack from petitions to the US Supreme Court filed by Acorda and Allergan.